WO2001032211A3 - Compose conjugue pour le traitement d'atheromes, de tumeurs et d'autres tissus neoplasiques - Google Patents

Compose conjugue pour le traitement d'atheromes, de tumeurs et d'autres tissus neoplasiques Download PDF

Info

Publication number
WO2001032211A3
WO2001032211A3 PCT/US2000/029524 US0029524W WO0132211A3 WO 2001032211 A3 WO2001032211 A3 WO 2001032211A3 US 0029524 W US0029524 W US 0029524W WO 0132211 A3 WO0132211 A3 WO 0132211A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
atheroma
conjugate compounds
treating
compounds
Prior art date
Application number
PCT/US2000/029524
Other languages
English (en)
Other versions
WO2001032211A2 (fr
Inventor
Jonathan L Sessler
Darren Madga
Original Assignee
Pharmacyclics Inc
Univ Texas
Jonathan L Sessler
Darren Madga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc, Univ Texas, Jonathan L Sessler, Darren Madga filed Critical Pharmacyclics Inc
Priority to AU12340/01A priority Critical patent/AU1234001A/en
Priority to EP00973891A priority patent/EP1223982A2/fr
Publication of WO2001032211A2 publication Critical patent/WO2001032211A2/fr
Publication of WO2001032211A3 publication Critical patent/WO2001032211A3/fr
Priority to US10/160,205 priority patent/US20030031676A1/en
Priority to HK03100643.8A priority patent/HK1050315A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des composés étant des conjugués a) d'une fraction capable de se localiser dans les cellules d'une tumeur ou d'un athérome et b) d'une fraction capable de catalyser la production d'espèces oxygène réactives d'un métabolite cellulaire. Les composés de l'invention sont utiles pour le traitement d'athéromes, de tumeurs et d'autres tissus néoplasiques.
PCT/US2000/029524 1999-10-29 2000-10-27 Compose conjugue pour le traitement d'atheromes, de tumeurs et d'autres tissus neoplasiques WO2001032211A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU12340/01A AU1234001A (en) 1999-10-29 2000-10-27 Conjugate compounds for treating atheroma, tumors and other neoplastic tissue
EP00973891A EP1223982A2 (fr) 1999-10-29 2000-10-27 Compose conjugue pour le traitement d'atheromes, de tumeurs et d'autres tissus neoplasiques
US10/160,205 US20030031676A1 (en) 1999-10-29 2002-05-30 Conjugate compounds for treating atheroma and other diseases
HK03100643.8A HK1050315A1 (zh) 1999-10-29 2003-01-24 用於治療粉瘤，腫瘤以及其他新生組織的共扼化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43129899A 1999-10-29 1999-10-29
US09/431,298 1999-10-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/160,205 Continuation US20030031676A1 (en) 1999-10-29 2002-05-30 Conjugate compounds for treating atheroma and other diseases

Publications (2)

Publication Number Publication Date
WO2001032211A2 WO2001032211A2 (fr) 2001-05-10
WO2001032211A3 true WO2001032211A3 (fr) 2002-03-07

Family

ID=23711325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029524 WO2001032211A2 (fr) 1999-10-29 2000-10-27 Compose conjugue pour le traitement d'atheromes, de tumeurs et d'autres tissus neoplasiques

Country Status (4)

Country Link
EP (1) EP1223982A2 (fr)
AU (1) AU1234001A (fr)
HK (1) HK1050315A1 (fr)
WO (1) WO2001032211A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116178456A (zh) * 2014-06-11 2023-05-30 德克萨斯州大学系统董事会 用于克服铂耐受性的德克萨卟啉-pt(iv)缀合物及组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587371A (en) * 1992-01-21 1996-12-24 Pharmacyclics, Inc. Texaphyrin-oligonucleotide conjugates
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
WO1999062551A1 (fr) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Conjugues de texaphyrine et utilisations associees
WO2001032210A2 (fr) * 1999-10-29 2001-05-10 Pharmacyclics, Inc. Methodes et compositions de traitement d'atheromes, de tumeurs et d'autres tissus neoplasiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587371A (en) * 1992-01-21 1996-12-24 Pharmacyclics, Inc. Texaphyrin-oligonucleotide conjugates
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
WO1999062551A1 (fr) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Conjugues de texaphyrine et utilisations associees
WO2001032210A2 (fr) * 1999-10-29 2001-05-10 Pharmacyclics, Inc. Methodes et compositions de traitement d'atheromes, de tumeurs et d'autres tissus neoplasiques

Also Published As

Publication number Publication date
WO2001032211A2 (fr) 2001-05-10
EP1223982A2 (fr) 2002-07-24
AU1234001A (en) 2001-05-14
HK1050315A1 (zh) 2003-06-20

Similar Documents

Publication Publication Date Title
WO1997029779A3 (fr) Conjugues de egf-genisteine pour le traitement du cancer
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
EP2348024A3 (fr) Procédé de préparation de conjugués cytotoxiques de maytansinoïdes et agents de liaison de cellules
WO2000066175A3 (fr) Nouveaux conjugues d'analogue de polyamine et conjugues de quinone, utilises pour le traitement de cancers et de maladies de la prostate
WO2001091798A3 (fr) Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers
WO1999043355A3 (fr) Formulations
AU2001227966A1 (en) Methods for treating tumors
WO2000002584A3 (fr) Procedes de traitement du cancer reposant sur l'utilisation d'anticorps vis-a-vis des aminophospholipides
EP2289940A3 (fr) Traitement de maladie métastatique
EP2062918A3 (fr) Compositions pharmaceutiques et procédés utiles pour moduler l'angiogénèse, inhiber la métastase et les fibroses de tumeur, et évaluer les tumeurs malignes parmi les tumeurs du cancer du colon
WO2000066528A3 (fr) Novel quinones utilisees dans le traitements de maladies
AU7380500A (en) Methods for treating tumors using neutron therapy
WO2002036601A3 (fr) Glycosidation d'un indolocarbazole catalysee par transfert de phase
AU1233701A (en) Methods and compositions for treating atheroma, tumors and other neoplastic tissue
AU3391200A (en) Compositions and methods for breast cancer therapy and diagnosis
WO2002043773A3 (fr) Promedicaments propres aux tissus
WO2000061756A3 (fr) Composes pour l'immunotherapie et le diagnostic du cancer du sein et procedes d'utilisation
WO2001032211A3 (fr) Compose conjugue pour le traitement d'atheromes, de tumeurs et d'autres tissus neoplasiques
AU6969098A (en) 1,2,4-benzotriazine oxides formulations
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
WO2003078607A3 (fr) Production et utilisation de signal-plexes specifiques de tissus pour differencier des cellules et les differencier de phenotypes imposes par le tissu d'origine du signal-plexe
AU2002224096A1 (en) Method of testing anticancer agent-sensitivity of tumor cells
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
AU2607999A (en) Sustained release implant, methods for preparation thereof and for treating cancer
WO2002029104A3 (fr) Marqueur tumoral et procedes d'utilisation de ce dernier

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000973891

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10160205

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000973891

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000973891

Country of ref document: EP